Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients

Soft Tissue Neoplasms Clinical Trial

Official title:

Treatment Response Evaluation in Patients With Gastrointestinal Stromal Tumor Using PET/CT and DW MRI

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01276483
• Other study ID #: REK-2010/2089
• Status: Completed
• Phase: N/A
• First received: January 12, 2011
• Last updated: June 21, 2017
• Start date: February 2011
• Est. completion date: June 21, 2017

Study information

• Verified date: June 2017
• Source: Oslo University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to compare sensitivity, specificity and accuracy of PET, DW MRI and CT separately and combined for the evaluation of treatment response and progression-free survival in patients with GIST.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: June 21, 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Metastatic GIST patients suitable for TKI treatment

• GIST patients pursuing preoperative neoadjuvant TKI treatment

Exclusion Criteria:

• Patients with contraindications to MRI and/or TKI treatment. For patients with renal failure, CT without intravenous contrast will be performed according to clinical practice.

• Patients who do not sign the consent paper for any reason or do not accept the study premises or patients who wish to withdraw for any reason during the study

Related Conditions & MeSH terms

• Gastrointestinal Stromal Tumors
• Gastrointestinal Tract
• Soft Tissue Neoplasms

Locations

Country	Name	City	State
Norway	Oslo University Hosptal	Oslo

Sponsors (1)

Lead Sponsor	Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Radiologic-pathologic correlation		2 years